Article
2'-Fluoro-6'-methylene-carbocyclic adenosine phosphoramidate (FMCAP) prodrug: in vitro anti-HBV activity against the lamivudine-entecavir resistant triple mutant and its mechanism of action.
Bioorganic & medicinal chemistry letters - 15 Jan 2013
Rawal Ravindra K, Singh Uma S, Chavre Satish N, Wang Jianing, Sugiyama Masaya, Hung Wai, Govindarajan Rajgopal, Korba Brent, Tanaka Yasuhito, Chu Chung K
Abstract excerpt
Novel 2'-fluoro-6'-methylene-carbocyclic adenosine (FMCA) monophosphate prodrug (FMCAP) was synthesized and evaluated for its in vitro anti-HBV potency against a lamivudine-entecavir resistant clone (L180M+M204V+S202G). FMCA demonstrated significant antiviral activity against wild-type as well as lamivudine-entecavir resistant triple mutant (L180M+M204V+S202G). The monophosphate prodrug (FMCAP) demonstrated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.